<DOC>
	<DOCNO>NCT00002675</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient retinoblastoma .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Retinoblastoma</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate response rate adjuvant carboplatin ( CBDCA ) alone child intraocular retinoblastoma . II . Assess overall survival , disease-free survival , time treatment failure patient . III . Attempt maintain 90 % disease-free survival rate treatment . IV . Estimate percentage disease-free survivor require use radiotherapy adjuvant CBDCA . V. Assess toxicity treatment . VI . Estimate percentage functional eye salvage use radiation-sparing protocol compare result , nonrandomized manner , historical treatment result population . OUTLINE : Patients stratify accord vitreous disease ( yes v ) . Patients receive carboplatin IV 1 hour day 0 . Treatment repeat every 2-3 week 2 course . Patients achieve complete response ( CR ) proceed local control measure consist cryotherapy , laser photocoagulation , etc . ( except brachytherapy ) . Patients achieve CR continue carboplatin local control measure feasible . Patients vitreous disease achieve CR receive 2 additional course receive local control measure . Patients vitreous disease achieve CR receive intensive chemotherapy . Patients receive intensive chemotherapy consist vincristine IV day 0 , 7 , 14 , cisplatin IV 6 hour day 0 , etoposide IV day 1 2 , follow cyclophosphamide IV 60 minute day 1 2 . Patients receive filgrastim ( G-CSF ) subcutaneously begin day 3 blood count recover . Treatment repeat every 2-4 week 2 course beyond CR . Patients follow 3 year . PROJECTED ACCRUAL : A total 50 patient accrue study 5-6 year .</detailed_description>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Intraocular retinoblastoma Ophthalmologic exam anesthesia within 3 week prior registration No pathologic confirmation require No evidence extraocular disease , i.e . : Negative head MRI CT ( contrast require ) Negative CSF cytology Negative bone marrow aspiration biopsy PATIENT CHARACTERISTICS : Age : Under 18 Performance status : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 2.0 mg/dl SGOT SGPT less 5 time upper limit normal Renal : Creatinine normal age OR Creatinine clearance great 50 ml/min PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>intraocular retinoblastoma</keyword>
</DOC>